Claims for Patent: 10,456,384

Summary for Patent: 10,456,384

Title:	Methods for treating irritable bowel syndrome (IBS)
Abstract:	The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
Inventor(s):	Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC)
Assignee:	Salix Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:	15/902,179
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,456,384
Patent Claims:	1. A method of treating one or more symptoms of irritable bowel syndrome (IBS) in a subject 65 years of age or older, said method comprising administering, for between 14 days and 24 months, 550 mg of rifaximin TID to the subject, thereby treating a symptom of IBS in the subject 65 years of age or older. 2. The method of claim 1, wherein the one or more symptoms are selected from one or more of cramping, pain, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and urgency. 3. The method of claim 1, wherein the IBS is diarrhea-predominant IBS. 4. The method of claim 1, wherein the IBS is alternating IBS. 5. The method of claim 1, wherein the treating one or more symptoms of IBS comprises a reduction of the one or more symptoms from baseline symptoms established prior to treatment. 6. The method of claim 5, wherein the reduction of the one or more symptoms is achieved following 7 days after the administration of rifaximin. 7. The method of claim 1, wherein treating one or more symptoms of IBS comprises a reduction in symptoms defined by an affirmative response from the subject when asked whether they had a reduction in symptoms of IBS. 8. The method of claim 2, wherein the IBS is diarrhea-predominant IBS. 9. The method of claim 8, wherein the treating one or more symptoms of IBS comprises a reduction of the one or more symptoms from baseline symptoms established prior to treatment. 10. The method of claim 9, wherein the reduction of the one or more symptoms is achieved following 7 days after the administration of rifaximin. 11. The method of claim 8, wherein treating one or more symptoms of IBS comprises a reduction in symptoms defined by an affirmative response from the subject when asked whether they had a reduction in symptoms of IBS. 12. The method of claim 2, wherein the IBS is alternating IBS. 13. The method of claim 12, wherein the treating one or more symptoms of IBS comprises a reduction of the one or more symptoms from baseline symptoms established prior to treatment. 14. The method of claim 13, wherein the reduction of the one or more symptoms is achieved following 7 days after the administration of rifaximin. 15. The method of claim 12, wherein treating one or more symptoms of IBS comprises a reduction in symptoms defined by an affirmative response from the subject when asked whether they had a reduction in symptoms of IBS.